Cannabinoid Encyclopedia

Focused research review

Cannabinoids and liver enzyme/hepatotoxicity: what the research says

What evidence connects cannabinoids with liver enzymes, hepatotoxicity, or hepatic safety monitoring?

Updated July 2026 12 research sources Human and early research

The short answer

What is the bottom line?

Research has examined Cannabinoids and liver enzyme/hepatotoxicity. This page brings together 8 human-study sources, 3 research reviews, and 1 lab, animal, or mechanism source. The source set includes human research as well as earlier-stage studies. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Cannabinoids and liver enzyme/hepatotoxicity.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Cannabinoids and liver enzyme/hepatotoxicity covers Endocannabinoid enzymes and metabolism; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Cannabinoids and liver enzyme/hepatotoxicity

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

Endocannabinoid enzymes and metabolism

This part of the literature focuses on Endocannabinoid enzymes and metabolism. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

8 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

3 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

1 source

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on Cannabinoids and liver enzyme/hepatotoxicity is not one kind of study. This source set includes 5 clinical studies in people, 2 cell or laboratory studies, 2 narrative or expert reviews, and 1 animal study. 3

The recorded populations or models include people or patients (7 sources), pediatric, adolescent, or developmental context (2 sources), and animal models (1 source). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is endocannabinoid enzyme activity or metabolic mechanisms (12 sources). Closely related outcome names can still describe different measurements. 5

The Cannabinoids and liver enzyme/hepatotoxicity source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

systematic review or meta-analysis

Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis.

On this page, this source examines CBD activity involving endocannabinoid enzyme activity or metabolic mechanisms. 1

Study type
systematic review or meta-analysis
Population or model
people or patients
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

animal study

Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine.

On this page, this source examines CBD activity involving endocannabinoid enzyme activity or metabolic mechanisms. 2

Study type
animal study
Population or model
animal models
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
mechanism-focused research

clinical study in people

Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise.

On this page, this source examines CBD activity involving endocannabinoid enzyme activity or metabolic mechanisms. 3

Study type
clinical study in people
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

clinical study in people

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.

On this page, this source examines CBD activity involving endocannabinoid enzyme activity or metabolic mechanisms. 4

Study type
clinical study in people
Population or model
pediatric, adolescent, or developmental context
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
human research

clinical study in people

Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial.

On this page, this source examines CBD activity involving endocannabinoid enzyme activity or metabolic mechanisms. 5

Study type
clinical study in people
Population or model
people or patients
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
mechanism-focused research

Safety and limits

What should readers keep in mind?

Research on Cannabinoids and liver enzyme/hepatotoxicity should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What evidence connects cannabinoids with liver enzymes, hepatotoxicity, or hepatic safety monitoring?

Relevant research is collected here. The source set includes human research as well as earlier-stage studies. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 8

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. systematic review or meta-analysis; evidence still limited PubMed 36912195 DOI 10.1111/joim.13627
  2. 2
    Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. animal study; mechanism-focused research PubMed 25999668 DOI 10.1155/2015/523418
  3. 3
    Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. clinical study in people; evidence still limited PubMed 39630203 DOI 10.1007/s00204-024-03904-1
  4. 4
    Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. clinical study in people; human research PubMed 29768152 DOI 10.1056/nejmoa1714631
  5. 5
    Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. clinical study in people; mechanism-focused research PubMed 33022751 DOI 10.1002/cpt.2071
  6. 6
    Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. clinical study in people; human research PubMed 40622698 DOI 10.1001/jamainternmed.2025.2366
  7. 7
    Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model. clinical study in people; mechanism-focused research PubMed 40774642 DOI 10.1016/j.tiv.2025.106126
  8. 8
    Observed Impact of Long-Term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults. human research PubMed 34918948 DOI 10.1089/can.2021.0114
  9. 9
    Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review. narrative or expert review; evidence still limited PubMed 39228144 DOI 10.1111/jgh.16730
  10. 10
    Metabolism and liver toxicity of cannabidiol. narrative or expert review; evidence still limited PubMed 38904421 DOI 10.1080/26896583.2024.2366741
  11. 11
    Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology. cell or laboratory study; mechanism-focused research PubMed 37458709 DOI 10.1002/cpt.3004
  12. 12
    Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip. cell or laboratory study; mechanism-focused research PubMed 40750820 DOI 10.1038/s41598-025-12846-2
See all 12 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. animal study; mechanism-focused research / 1 linked research note PubMed 25999668
  2. Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37458709
  3. Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. clinical study in people; evidence still limited / 1 linked research note PubMed 39630203
  4. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. clinical study in people; human research / 1 linked research note PubMed 29768152
  5. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. clinical study in people; human research / 1 linked research note PubMed 40622698
  6. Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. clinical study in people; mechanism-focused research / 1 linked research note PubMed 33022751
  7. Observed Impact of Long-Term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults. human research / 1 linked research note PubMed 34918948
  8. Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40750820
  9. Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model. clinical study in people; mechanism-focused research / 1 linked research note PubMed 40774642
  10. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 36912195
  11. Metabolism and liver toxicity of cannabidiol. narrative or expert review; evidence still limited / 1 linked research note PubMed 38904421
  12. Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review. narrative or expert review; evidence still limited / 1 linked research note PubMed 39228144